Cargando…

Potential Psychiatric Uses for MDMA

Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazar‐Klosinski, BB, Mithoefer, MC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260336/
https://www.ncbi.nlm.nih.gov/pubmed/27859039
http://dx.doi.org/10.1002/cpt.565
_version_ 1782499388530098176
author Yazar‐Klosinski, BB
Mithoefer, MC
author_facet Yazar‐Klosinski, BB
Mithoefer, MC
author_sort Yazar‐Klosinski, BB
collection PubMed
description Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches.
format Online
Article
Text
id pubmed-5260336
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52603362017-01-26 Potential Psychiatric Uses for MDMA Yazar‐Klosinski, BB Mithoefer, MC Clin Pharmacol Ther Developments Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches. John Wiley and Sons Inc. 2017-01-13 2017-02 /pmc/articles/PMC5260336/ /pubmed/27859039 http://dx.doi.org/10.1002/cpt.565 Text en © 2016, The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Developments
Yazar‐Klosinski, BB
Mithoefer, MC
Potential Psychiatric Uses for MDMA
title Potential Psychiatric Uses for MDMA
title_full Potential Psychiatric Uses for MDMA
title_fullStr Potential Psychiatric Uses for MDMA
title_full_unstemmed Potential Psychiatric Uses for MDMA
title_short Potential Psychiatric Uses for MDMA
title_sort potential psychiatric uses for mdma
topic Developments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260336/
https://www.ncbi.nlm.nih.gov/pubmed/27859039
http://dx.doi.org/10.1002/cpt.565
work_keys_str_mv AT yazarklosinskibb potentialpsychiatricusesformdma
AT mithoefermc potentialpsychiatricusesformdma